Regen Biologics' collagen meniscus implant shows promise in early studies, CEO says.
This article was originally published in The Gray Sheet
Executive Summary
ReGEN BIOLOGICS' COLLAGEN MENISCUS IMPLANT FEASIBILITY STUDY resulted in seven of nine patients describing their knees as "nearly normal" after treatment with the implant, ReGen Chief Executive Officer Michael Egan reported at the Hambrecht & Quist life sciences conference in San Francisco. In addition, seven of nine patients showed "marked improvement from their pre-op status," and all patients returned to activities of daily living with minimal or no pain.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.